Back
IN THE HIGH COURT OF DELHI AT NEW DELHI
Purushaindra Kumar Kaurav, J
Cipla Limited – Appellant
Versus
National Pharmaceutical Pricing Authority – Respondent
| Table of Content |
|---|
| 1. overview of the dispute regarding the timing of drug manufacture versus price notification. (Para 1 , 2 , 3) |
| 2. court's mandate to ensure procedural fairness and the requirement for an opportunity of hearing prior to adverse findings. (Para 4 , 5 , 6 , 7 , 8 , 9) |
O R D E R
1. The grievance raised by the petitioner in all the writ petitions is that the manufacturing of the drug was prior to issuance of ceiling price notification by National Pharmaceutical Pricing Authority (‘NPPA’).
2. Learned counsel for the petitioner has presented following brief note of facts to explain the aforesaid position:
“BRIEF NOTE ON FACTS”
| Item No. | WP (C) No. | Impugned Batch No. & date of manufacturing by the Petitioner | Ceiling Price Notification issued by NPPA | Form V issued by Petitioner on | Date of alleged purchase by the NPPA | Product Name |
|---|---|---|---|---|---|---|
| 62 | 208/2026 | SA22815; Oct. 2022 | SO No. 194(E); dt. 11.01.2023 | 12.01.2023 [PDF 230] | 25.05.2023 | Forcan 150mg |
| 63 | 209/2026 | AFC22029; June 2022 | SO No. 87(E); dt. 06.01.2023 | 09.01.2023 [PDF 88] | 20.10.2023 | Cipmox CV |
| 64 | 211/2026 | D2031; April 2022 | SO No. 1579(E); dt. 31.03.2023 (w.e.f. 01.04.2023) | 02.04.2023 [PDF 112] | 21.07.2023 | Terbicip |
| 65 | 212/2026 | K | ||||
An indispensable Tool for Legal Professionals, Endorsed by Various High Court and Judicial Officers
Please visit our Training & Support
Center or Contact Us for assistance
Scan Me!
India’s Legal research and Law Firm App, Download now!
For Daily Legal Updates, Join us on :
Back to top
